

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT – UPDATE ON THE COMPANY’S PRODUCT REVENUE IN THE THIRD QUARTER OF 2022

This announcement is made by Innovent Biologics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

In the third quarter of 2022, the Company achieved a total product revenue of over RMB1.1 billion. Our product portfolio demonstrated a dual growth in both sales volume and revenue on a quarter-to-quarter basis. Among them, the sales volume and revenue of TYVYT[®] (sintilimab injection) achieved growth on a quarter-to-quarter basis, and the contribution of new indications for first-line gastric cancer and first-line esophageal cancer increased. Other drug products continued to ramp up, market coverage as well as access continued to increase, and the synergistic value became increasingly prominent, laying a solid foundation for the continuous growth of the Company’s commercial product portfolio.

Since the beginning of the year, the Company has proactively sought to explore a more sustainable and healthier commercial business model by establishing an agile and lean organization structure with refined, systematic and scientific management aiming to further enhance productivity as well as improve efficiency. The Company believes that our sound operational capabilities and model enable us to effectively increase the scale of business while improving efficiency at the same time, ensure the realization of our product value of innovative pipelines, realize the long-term sustainable development of our business as well as support the Company’s long term strategies.

The Company has owned eight approved products, including: TYVYT[®] (sintilimab injection), BYVASDA[®] (bevacizumab biosimilar injection), SULINNO[®] (adalimumab biosimilar injection), HALPRYZA[®] (rituximab biosimilar injection), PEMAZYRE[®] (pemigatinib), NAILIKE (Olverematinib), Cyramza[®] (ramucirumab) and Selpercatinib (highly-selective RET inhibitor).

The Company has built a robust pipeline of 35 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 8 products officially approved for marketing in China, 2 assets under New Drug Application review by National Medical Products Administration, 4 assets in Phase 3 or pivotal clinical trials, and additional 21 molecules in clinical trials. The Company believes the robust pipeline with great market potential will support the sustainable growth of the Company under the committed strategy of global innovation.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China, November 1, 2022

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen and Mr. Gary Zieziula as Independent Non-executive Directors.